{
    "2019-09-20": [
        [
            {
                "time": "2023-10-18",
                "original_text": "UPDATE 2-Novo Nordisk wins U.S. approval for first-of-its-kind oral diabetes drug",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "U.S. approval",
                        "first-of-its-kind",
                        "oral diabetes drug"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "UPDATE 2-European shares log fifth week of gains, Novo Nordisk shines",
                "features": {
                    "keywords": [
                        "European shares",
                        "fifth week of gains",
                        "Novo Nordisk"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "stocks"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}